This website uses cookies and other technologies to personalize content and ads on this and other websites and provide social media features. By clicking "I Agree" you consent to our use of tracking technologies and disclosure of tracking data to third party ad networks or social media companies for the purposes above. If you click "I Disagree" you can still use this website. For more information about Lilly’s privacy practice and to manage third-party preferences, click here.

BASAGLAR® (insulin glargine injection) 100 units/mL has no dosing differences with Lantus® (insulin glargine injection) 100 units/mL for insulin initiation1,5

Once-daily dose at the same time each day1

Type 2 diabetes1 recommended starting dose

0.2 units/kg once daily or up to 10 units once daily

  • Adjustments to the amount and timing of short- or rapid-acting insulins and dosages of any anti-diabetic medications may be necessary

Type 1 diabetes1 recommended starting dose

~1/3 of the total daily insulin requirements

  • Short- or rapid-acting, premeal insulin should be used to satisfy the remainder of the daily insulin requirements
  • BASAGLAR must be used concomitantly with short-acting insulin

SELECT SAFETY INFORMATION
WARNINGS AND PRECAUTIONS
BASAGLAR prefilled pens must never be shared between patients, even if the needle is changed. Sharing poses a risk of transmission of blood borne pathogens.

Other dosing information

  • Inject BASAGLAR subcutaneously once a day, any time of day, at the same time every day
  • Individualize and titrate BASAGLAR dosage based on the metabolic needs, blood glucose monitoring results, and glycemic control goal of the individual
  • Dosage adjustments may be needed with changes in physical activity, changes in meal patterns (i.e., macronutrient content or timing of food intake), during acute illness, or changes in renal or hepatic function, and should be made under medical supervision with appropriate glucose monitoring

SELECT SAFETY INFORMATION
CONTRAINDICATIONS
BASAGLAR is contraindicated during episodes of hypoglycemia, and in patients with hypersensitivity to insulin glargine or one of its excipients.

Titrate BASAGLAR to target fasting plasma glucose (FPG) levels

Increase dose by 1 unit daily until target FPG level is achieved (≤100mg/dL or FPG based on goal of individual patient)2,10

  • Dose titration of BASAGLAR should be individualized according to patient needs and performed under the guidance of a healthcare professional
  • In the event of hypoglycemia, a dose reduction may be necessary

SELECT SAFETY INFORMATION
WARNINGS AND PRECAUTIONS
BASAGLAR KwikPen® must never be shared between patients, even if the needle is changed. Sharing poses a risk of transmission of blood borne pathogens.

Transitioning to BASAGLAR from other insulins1

From Lantus® (insulin glargine injection) 100 units/mL

  • The dose of BASAGLAR should be the same as Lantus
  • The time of day for administration should be determined by the healthcare professional

From Toujeo® (insulin glargine injection) 300 units/mL

  • The recommended initial BASAGLAR dosage is 80% of the Toujeo dose that is being discontinued
  • This dosage reduction will lower the likelihood of hypoglycemia

From NPH (neutral protamine Hagedorn) insulin (twice-daily)

  • The recommended initial BASAGLAR dosage is 80% of the NPH dosage that is being discontinued
  • This dosage reduction will lower the likelihood of hypoglycemia

From intermediate- or long-acting insulin other than Lantus

  • A change in the dose of BASAGLAR may be required and the amount and timing of shorter-acting insulins and doses of any anti-diabetic drugs may need to be adjusted.

SELECT SAFETY INFORMATION
WARNINGS AND PRECAUTIONS
Changes in insulin strength, manufacturer, type, or method of administration may affect glycemic control and predispose to hypoglycemia or hyperglycemia. These changes should be made cautiously and only under close medical supervision, and the frequency of blood glucose monitoring should be increased. For patients with type 2 diabetes, dosage adjustments of concomitant anti-diabetic products may be needed.

Begin with the BASAGLAR prefilled KwikPen®

BASAGLAR (insulin glargine injection) 100 units/mL prefilled KwikPen<sup>®</sup> with information about product features

BASAGLAR KwikPen must never be shared between patients, even if the needle is changed. Sharing poses a risk of transmission of blood borne pathogens.1

In patients with type 1 diabetes, BASAGLAR must be used concomitantly with short-acting insulin.1

*Multiple sizes may be used.

†In a study, the 4 mm x 32 G Pen Needle provided equivalent glycemic control with reduced pain compared to longer and thicker needles.12

‡Do not freeze or use a KwikPen that has been frozen.

By watching this video with your patients, you can help them learn how to use and store their Basaglar KwikPen. It walks them through steps to prepare, prime, dose, inject, and clean up. This video must be used with the complete Instructions for Use included with the pen.

Support for your patients

Indication and Important Safety Information
Indication

BASAGLAR is indicated to improve glycemic control in adults and pediatric patients with type 1 diabetes mellitus and in adults with type 2 diabetes mellitus.

LIMITATION OF USE

BASAGLAR is not recommended for the treatment of diabetic ketoacidosis.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

BASAGLAR is contraindicated during episodes of hypoglycemia, and in patients with hypersensitivity to insulin glargine or one of its excipients.

WARNINGS AND PRECAUTIONS

BASAGLAR prefilled pens must never be shared between patients, even if the needle is changed. Sharing poses a risk of transmission of blood borne pathogens.


Changes in insulin strength, manufacturer, type, injection site, or method of administration may affect glycemic control and predispose to hypoglycemia or hyperglycemia. Any changes in insulin regimen should be made cautiously and only under close medical supervision, and the frequency of blood glucose monitoring should be increased. Due to reports of hypoglycemia and hyperglycemia, advise patients who have repeatedly injected into areas of lipodystrophy or localized cutaneous amyloidosis to change the injection site to unaffected areas and closely monitor blood glucose. For patients with type 2 diabetes, dosage adjustments of concomitant anti-diabetic products may be needed.


Hypoglycemia is the most common adverse reaction associated with insulins, including BASAGLAR. Severe hypoglycemia can cause seizures, may be life-threatening, or cause death.


Accidental mix-ups between another insulin glargine product (100 units/mL) and other insulins, particularly rapid-acting insulins, have been reported. To avoid medication errors between BASAGLAR and other insulins, instruct patients to always check the insulin label before each injection.


Severe, life-threatening, generalized allergy, including anaphylaxis, can occur with insulin products, including BASAGLAR. If hypersensitivity reactions occur, discontinue BASAGLAR; treat per standard of care and monitor until symptoms and signs resolve. BASAGLAR is contraindicated in patients who have had hypersensitivity reactions to insulin glargine or one of the excipients.


All insulin products, including BASAGLAR, cause a shift in potassium from the extracellular to intracellular space, possibly leading to hypokalemia. Untreated hypokalemia may cause respiratory paralysis, ventricular arrhythmia, and death. Monitor potassium levels in patients at risk for hypokalemia if indicated.


Thiazolidinediones (TZDs), which are peroxisome proliferator-activated receptor (PPAR)-gamma agonists, can cause dose-related fluid retention, particularly when used in combination with insulin. Fluid retention may lead to or exacerbate heart failure. These patients should be observed for signs and symptoms of heart failure. If heart failure occurs, dosage reduction or discontinuation of TZD must be considered.

ADVERSE REACTIONS

Adverse reactions commonly associated with insulin glargine products (5% or greater incidence) are: hypoglycemia, allergic reactions, injection site reaction, lipodystrophy, pruritus, rash, edema, and weight gain.

DRUG INTERACTIONS

Certain drugs may affect glucose metabolism, requiring insulin dose adjustment and close monitoring of blood glucose. The signs and symptoms of hypoglycemia may be blunted when beta-blockers, clonidine, guanethidine, and reserpine are co-administered with BASAGLAR.

BV HCP ISI 25NOV2019

For more information, please see Full Prescribing Information and Patient Information. Please see Instructions for Use.

References
1. BASAGLAR [Prescribing Information]. Indianapolis, IN: Eli Lilly and Company. 2. Rosenstock J, Hollander P, Bhargava A, et al. Diabetes Obes Metab. 2015;17:734-741. 3. Data on file, Lilly USA, LLC. BAS20160408A. 4. Data on file, Lilly USA, LLC. BAS20160811B. 5. Lantus [Prescribing Information]. Bridgewater, NJ: sanofi-aventis U.S. LLC; 2018. 6. Linnebjerg H, Lam EC, Seger ME, et al. Diabetes Care. 2015;38:2226-2233. 7. Blevins TC, Dahl D, Rosenstock J, et al. Diabetes Obes Metab. 2015;17:726-733. 8. Data on file, Lilly USA, LLC. BAS20151103E. 9. Data on file, Lilly USA, LLC. BAS20160811A. 10. Gerstein HC, Yale JF, Harris SB, et al. Diabet Med. 2006;23:736-742. 11. BASAGLAR KwikPen [Instructions for Use]. Indianapolis, IN: Eli Lilly and Company. 12. Hirsch LJ, Gibney MA, Qu S, et al. Curr Med Res Opin. 2010;26(6):1531-1541. 13. Fischer MA, Stedman MR, Lii J, et al. J Gen Intern Med. 2010;25(4):284-290. 14. Data on file, Lilly USA, LLC. DOF-BV-US-0002.

Are you a US Healthcare provider?

The information contained in this section of basaglar.com is intended for US Healthcare providers. Please confirm below.

You are now leaving basaglar.com.

The link you clicked on will take you to a site maintained by a third party, which is solely responsible for its content. Lilly USA, LLC does not control, influence, or endorse this site, and the opinions, claims, or comments expressed on this site should not be attributed to Lilly USA, LLC. Lilly USA, LLC is not responsible for the privacy policy of any third-party websites. We encourage you to read the privacy policy of every website you visit.

Click “Continue” to leave site or “Return to basaglar.com” to close this window and return to basaglar.com.